stockrowPrivia Health Group, Inc.
PRVA Healthcare Health Information Services
Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024.
- Revenue
- +13.2%
- EPS
- +83.3%
- Free cash flow
- −44.4%
Quarter to September 2026, against a year earlier
Follow PRVA
Alert me
Privia Health Group, Inc. (PRVA) Revenue
Privia Health Group, Inc.'s revenue for fiscal 2025 was $2.1B, up 22.3% from $1.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.4B. Over the past ten years it has ranged from $658.0M (fiscal 2018) to $2.1B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 7 consecutive fiscal years. Privia Health Group, Inc. ranks 4th of 42 Health Information Services companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.1B | 22.26% |
| FY2024 | $1.7B | 4.74% |
| FY2023 | $1.7B | 22.19% |
| FY2022 | $1.4B | 40.41% |
| FY2021 | $966.2M | 18.25% |
| FY2020 | $817.1M | 3.91% |
| FY2019 | $786.4M | 19.51% |
| FY2018 | $658.0M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $657.0M | 3.85% |
| Jun 2026 | $632.6M | 4.77% |
| Mar 2026 | $603.8M | 11.58% |
| Dec 2025 | $541.2M | (6.76%) |
| 23 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TDOC Teladoc Health, Inc. compare | $2.5B |
| PRVA Privia Health Group, Inc. | $2.4B |
| WAY Waystar Holding Corp. compare | $1.3B |
| OMCL Omnicell, Inc. compare | $1.2B |
| GDRX GoodRx Holdings, Inc. compare | $785.2M |
| DOCS Doximity, Inc. compare | $661.6M |
| CERT Certara, Inc. compare | $398.7M |
| SDGR Schrodinger, Inc. compare | $269.2M |
| HTFL Heartflow, Inc. compare | $212.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on PRVA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement